clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Ureteral Obstruction D014517 10 associated lipids
Rodent Diseases D012376 4 associated lipids
Osteomyelitis D010019 10 associated lipids
Pancreatitis D010195 10 associated lipids
Skin Ulcer D012883 6 associated lipids
Cysts D003560 4 associated lipids
Urination Disorders D014555 9 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Abnormalities, Drug-Induced D000014 10 associated lipids
Cell Transformation, Neoplastic D002471 126 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Kunin M et al. Mycobacterium chelonae peritonitis in peritoneal dialysis. Literature review. 2014 Eur. J. Clin. Microbiol. Infect. Dis. pmid:24569948
Yakoob J et al. Comparison of antimicrobial activity of zinc chloride and bismuth subsalicylate against clinical isolates of Helicobacter pylori. 2014 Microb. Drug Resist. pmid:23844851
Khoshnood A et al. Replacement of clarithromycin with azithromycin in triple therapy regimens for the eradication of Helicobacter pylori: A randomized clinical trial. 2014 J Med Life pmid:25408735
Fowler J and Mahlen SD Localized cutaneous infections in immunocompetent individuals due to rapidly growing mycobacteria. 2014 Arch. Pathol. Lab. Med. pmid:25076301
Ueda Y et al. [Obstructive pneumonia and brain abscess due to Nocardia elegans in a patient with systemic lupus erythematosus]. 2014 Kansenshogaku Zasshi pmid:24974451
Negrín-González J et al. Psychiatric adverse reaction induced by clarithromycin. 2014 Eur Ann Allergy Clin Immunol pmid:24853570
Kurosaki Y et al. [Two cases of pulmonary Mycobacterium avium complex disease with resistance to clarithromycin]. 2014 Kekkaku pmid:24979948
Tümgör G et al. Comparison of standard and standard plus vitamin E therapy for Helicobacter pylori eradications in children. 2014 Turk J Gastroenterol pmid:25910378
Çiftci İH et al. Comparison of FISH, RFLP and agar dilution methods for testing clarithromycin resistance of Helicobacter pylori. 2014 Turk J Gastroenterol pmid:25910373
Zhou L et al. A comparative study of sequential therapy and standard triple therapy for Helicobacter pylori infection: a randomized multicenter trial. 2014 Am. J. Gastroenterol. pmid:24642580
Heo J and Jeon SW [Changes in the eradication rate of conventional triple therapy for Helicobacter pylori infection in Korea]. 2014 Korean J Gastroenterol pmid:24651586
Kang BK et al. [New therapeutic strategies against Helicobacter pylori]. 2014 Korean J Gastroenterol pmid:24651587
Lee JY and Kim N [Future trends of Helicobacter pylori eradication therapy in Korea]. 2014 Korean J Gastroenterol pmid:24651589
Patsche CB et al. Disseminated Mycobacterium celatum disease with prolonged pulmonary involvement. 2014 Int. J. Infect. Dis. pmid:25008771
Mendu ML and Waikar SS Drug-drug interactions and acute kidney injury: caveat prescriptor. 2014 Am. J. Kidney Dis. pmid:24820318
Furuta T et al. Sitafloxacin-based third-line rescue regimens for Helicobacter pylori infection in Japan. 2014 J. Gastroenterol. Hepatol. pmid:24224808
Noguchi S et al. Polymorphic transformation of antibiotic clarithromycin under acidic condition. 2014 J Pharm Sci pmid:24375227
Phillips RO et al. Clinical and bacteriological efficacy of rifampin-streptomycin combination for two weeks followed by rifampin and clarithromycin for six weeks for treatment of Mycobacterium ulcerans disease. 2014 Antimicrob. Agents Chemother. pmid:24323473
Hajaghamohammadi A et al. Low dose furazolidone for eradication of H- pylori instead of clarithromycin: a clinical trial. 2014 Glob J Health Sci pmid:25560342
Iwanczak B et al. Genotypic and clinical differences of seropositive Helicobacter pylori children and adults in the Polish population. 2014 J. Physiol. Pharmacol. pmid:25554984
Rakici H et al. Comparison of levofloxacin- and moxifloxacin-based triple therapies with standard treatment in eradication of Helicobacter pylori as first-line therapy. 2014 Digestion pmid:25547786
Gold BD Resistance testing for Helicobacter pylori infection: is it finally ready for prime time? 2014 J. Pediatr. Gastroenterol. Nutr. pmid:25222802
Morakul B et al. Dissolution enhancement and in vitro performance of clarithromycin nanocrystals produced by precipitation-lyophilization-homogenization method. 2014 Eur J Pharm Biopharm pmid:25201298
Parekh TM et al. Hypoglycemia after antimicrobial drug prescription for older patients using sulfonylureas. 2014 JAMA Intern Med pmid:25179404
Kutluk G et al. Sequential therapy versus standard triple therapy for Helicobacter pylori eradication in children: any advantage in clarithromycin-resistant strains? 2014 Eur J Gastroenterol Hepatol pmid:25171023
Lambert D et al. Gastritis due to Helicobacter pylori, an unusual cause of chronic diarrhoea in HIV infected patients. 2014 Med Mal Infect pmid:25015308
Teh X et al. Functional and molecular surveillance of Helicobacter pylori antibiotic resistance in Kuala Lumpur. 2014 PLoS ONE pmid:25003707
Rasheed F et al. Analysis of clinical isolates of Helicobacter pylori in Pakistan reveals high degrees of pathogenicity and high frequencies of antibiotic resistance. 2014 Helicobacter pmid:24827414
Wang Y et al. Efficacy and safety of ecabet sodium as an adjuvant therapy for Helicobacter pylori eradication: a systematic review and meta-analysis. 2014 Helicobacter pmid:24826809
Pan-In P et al. Ethyl cellulose nanoparticles: clarithomycin encapsulation and eradication of H. pylori. 2014 Carbohydr Polym pmid:24815396
Ichihara A et al. Case of disseminated cutaneous Mycobacterium chelonae infection mimicking cutaneous vasculitis. 2014 J. Dermatol. pmid:24801916
Okame M et al. Complete regression of early-stage gastric diffuse large B-cell lymphoma in an HIV-1-infected patient following Helicobacter pylori eradication therapy. 2014 Clin. Infect. Dis. pmid:24585569
Mark TM et al. Thalidomide, clarithromycin, lenalidomide and dexamethasone therapy in newly diagnosed, symptomatic multiple myeloma. 2014 Leuk. Lymphoma pmid:24576165
Takazono T et al. Paradoxical response to disseminated non-tuberculosis mycobacteriosis treatment in a patient receiving tumor necrosis factor-α inhibitor: a case report. 2014 BMC Infect. Dis. pmid:24576098
Ali Habib HS et al. Effect of sequential versus standard Helicobacter pylori eradication therapy on the associated iron deficiency anemia in children. 2013 Sep-Oct Indian J Pharmacol pmid:24130381
Mégraud F Current recommendations for Helicobacter pylori therapies in a world of evolving resistance. 2013 Nov-Dec Gut Microbes pmid:23929066
Suzaki I et al. Enhancement of thioredoxin production from nasal epithelial cells by the macrolide antibiotic, clarithromycin in vitro. 2013 May-Jun In Vivo pmid:23606690
Dajani AI et al. Do probiotics improve eradication response to Helicobacter pylori on standard triple or sequential therapy? 2013 May-Jun Saudi J Gastroenterol pmid:23680708
Petitto J et al. Successful clarithromycin desensitization in a macrolide-sensitive pediatric patient. 2013 May-Jun J Allergy Clin Immunol Pract pmid:24565493
Cottle LE et al. A multinational outbreak of histoplasmosis following a biology field trip in the Ugandan rainforest. 2013 Mar-Apr J Travel Med pmid:23464714
Molina-Infante J and Gisbert JP [Update on the efficacy of triple therapy for Helicobacter pylori infection and clarithromycin resistance rates in Spain (2007-2012)]. 2013 Jun-Jul Gastroenterol Hepatol pmid:23623461
Razafimahefa SH et al. [Helicobacter pylori: what eradication regimen in a tropical area after the failure of two separate lines of eradication including metronidazole and clarithromycin?]. 2013 Jan-Mar Med Sante Trop pmid:23360589
Mandras N et al. Antibacterial efficacy and drug-induced tooth discolouration of antibiotic combinations for endodontic regenerative procedures. 2013 Apr-Jun Int J Immunopathol Pharmacol pmid:23755774
Krashias G et al. Prevalence of Helicobacter pylori cagA and vacA genes in Cypriot patients. 2013 J Infect Dev Ctries pmid:24042099
Evdokimova AG et al. [New approaches to therapy of Helicobacterpylori infection (by the materials of the Maastricht Consensus-IV, Florence, 2010)]. 2013 Antibiot. Khimioter. pmid:24640139
Shinahara W et al. Immunomodulator clarithromycin enhances mucosal and systemic immune responses and reduces re-infection rate in pediatric patients with influenza treated with antiviral neuraminidase inhibitors: a retrospective analysis. 2013 PLoS ONE pmid:23875018
Sarkeshikian SS et al. Azithromycin based triple therapy versus standard clarithromycin based triple therapy in eradication of Helicobacter pylori infection in Iran: a randomized controlled clinical trial. 2013 Turk J Gastroenterol pmid:23794338
Lai J et al. Epithelioid histiocytic infiltrate caused by Mycobacterium scrofulaceum infection: a potential mimic of various neoplastic entities. 2013 Am J Dermatopathol pmid:22935892
Boyanova L et al. Living in Sofia is associated with a risk for antibiotic resistance in Helicobacter pylori: a Bulgarian study. 2013 Folia Microbiol. (Praha) pmid:23580173
Bradbeer L et al. Childhood headache and H. pylori--a possible association. 2013 Aust Fam Physician pmid:23529524